Roth Capital Resumes IRadimed Corp (IRMD) at Buy

Roth Capital resumes coverage on IRadimed Corp (NASDAQ: IRMD) with a Buy rating and a price target of $16.00.

Analyst Scott Henry comes back to the name noting the base pump business is on track just above consensus expectations and believes the launch of non-magnetic vital signs monitor in the US has the potential to double to company's revenue base.

For an analyst ratings summary and ratings history on IRadimed Corp click here. For more ratings news on IRadimed Corp click here.

Shares of IRadimed Corp closed at $13.78 yesterday.

You May Also Be Interested In

• Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
• Freedom Broker Starts Carnival Corporation (CCL) at Buy
• UBS Downgrades Fonterra Co-operative Group Ltd (FSF:NZ) to Neutral